Developing personalized adjuvant treatment strategies for early-stage breast cancer: Addressing a clear unmet medical need

Inbiomotion focuses on providing a unique companion diagnostic solution, to address an urgent and unmet medical need in the personalized adjuvant treatment of early-stage breast cancer.

Founded in 2010 by Prof. Roger Gomis, Inbiomotion is a spin-off of IRB Barcelona and ICREA research institutions.

Our unique diagnostic assay is based on a highly selective, single-gene biomarker, of the MAF gene. The MAF test has the potential to identify early-stage breast cancer patients who will benefit from bisphosphonate adjuvant treatment, with the aim to improve their overall and disease-free survival, while excluding patients who will not benefit or can be harmed. It can further predict, at an early stage, a patient's risk of metastases relapse from primary tumors.


Inbiomotion appoints Ralf van den Berg as Chief Operating Officer

Ralf van den Berg will lead the development and execution of Inbiomotion's strategy while managing daily operations.  In his new role, Ralf van den Berg will drive Inbiomotion in his aim to position MAFTEST® for routine characterization of breast cancer tumors.

More news

Our innovation

Inbiomotion has discovered and validated MAF, a unique biomarker predictive of clinical benefit of adjuvant bisphosphonates in early breast cancer patients.
MAF allows selection of early-stage breast cancer patients benefiting from adjuvant bisphosphonate treatment using Inbiomotion proprietary diagnostic assay MAF Test®:

  • MAF negative patients will be eligible for Clodronate adjuvant treatment in early breast cancer, including non-post-menopausal patients currently not recommend in guidelines.
  • MAF positive patients will be excluded from Clodronate adjuvant treatment, including post-menopausal patients who do not benefit or may be harmed.

Selection of MAF negative patients for treatment with bisphosphonates could have a deep impact on the outcome of early breast cancer patients, reducing in a 35% the number of deaths of patients treated with standard chemo/hormonal therapies.